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Local cellular immune defects have been described in
several tumors including human papillomavirus (HPV)-
associated cervical cancer. This observation suggests the
potential therapeutic benefit of immune manipulations
that restore cellular immunity. Here, we evaluated the
ability of bispecific monoclonal antibodies (bimAbs) to
redirect T cells against keratinocytes transformed in
vitro by HPV in an autologous three-dimensional cul-
ture model (organotypic cultures). The epidermal
growth factor receptor (EGFR) was chosen as target for
an anti-CD3/anti-EGFR bimAb because it is overex-
pressed in many malignant epithelial lesions and only
weakly expressed in the basal layers of normal squa-
mous epithelium. Interestingly, in organotypic cul-
tures, the pattern of expression of EGFR was similar to
that observed in vivo. The ability of T cells retargeted by
CD3/EGFR bimAb to lyse HPV-transformed cell lines
was confirmed in monolayer cultures. In autologous
organotypic cultures, an increase in apoptotic HPV
keratinocytes and a significant decrease in the thickness
of HPV organotypic cultures were observed when ac-
tivated lymphocytes and bimAbs were added to the cul-
tures, whereas organotypic cultures of normal keratin-
ocytes were not significantly affected. These data were
similar to those obtained in the allogeneic model. These
results suggest the potential usefulness of CD3-EGFR
bimAb-retargeted lymphocytes in immunotherapeutic
protocols for malignant epithelial lesions. (Am J
Pathol 2002, 160:113–122)
The cellular immune response against tumors is, in most
cases, weak and mostly inefficient.1 Bispecific monoclo-
nal antibodies (bimAbs) have significant potential utility in
human tumor immunotherapy as a tool for retargeting
cytotoxic effector cells against tumor cells.2 Indeed, cy-
totoxic lymphocytes can be recruited to kill tumor cells if
they are retargeted by bimAb that binds both to the CD3
molecule associated with the T-cell receptor (TCR) com-
plex and to a specific molecule expressed on the target
cell surface.
Epidermal growth factor receptor (EGFR) is consid-
ered a suitable target molecule for antibody-driven im-
munotherapy because it is highly overexpressed in epi-
thelial tumors.3,4 EGFR overexpression was reported to
maintain a proliferative pool of basal cells and to prevent
the terminal differentiation of these cells in epidermal
tumors.5 An anti-CD3/anti-EGFR bimAb was generated
and its efficacy in T cell retargeting has been docu-
mented in other tumor models in vitro and in vivo.6
Several parameters, such as cell-cell contacts and
effector cell penetration of the tumors can dramatically
affect the efficacy of bimAb-based immunotherapeutic
protocols. Thus, preclinical in vitro and in vivo models that
closely mimic the in vivo environment of the tissue of
origin are prerequisite to validate new potentially thera-
peutic tools. Uterine cervical cancer is a good model to
evaluate immunotherapy protocols, because the etiolog-
ical agent of this tumor, the human papillomavirus (HPV),
has been well-defined.7,8 This cancer is preceded by
well-characterized preneoplastic stages designated as
squamous intraepithelial lesions. Moreover, several HPV
proteins induce overexpression of EGFR by different
mechanisms9,10 and this overexpression is associated
with poor prognosis in cervical carcinomas.11
The organotypic (raft) culture system has been in-
creasingly used to examine the effects of viral or bio-
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chemical therapeutic agents on a variety of malignant
keratinocytes.12–15 The raft technique permits cell prolif-
eration and differentiation at an air-liquid interface on a
dermal equivalent support. Normal keratinocytes stratify
and fully differentiate in a manner similar to the normal
squamous epithelial tissues, whereas HPV-immortalized
and established squamous carcinoma cell lines exhibit
dysplastic morphologies similar to high-grade lesions
seen in vivo.16–18 Furthermore, we recently demonstrated
that allogeneic activated lymphocytes are able to pene-
trate into raft cultures of squamous carcinoma cell
lines.15 To evaluate the retargeting ability of anti-CD3/
anti-EGFR bimAb in a three-dimensional model and to
avoid the potentially confounding effects of an allogeneic
immune response, we set up a model with newly estab-
lished HPV cell lines and autologous effector cells. Our
results indicate that bimAb-retargeted autologous lym-
phocytes induce apoptosis of autologous transformed




The anti-CD3/anti-EGF-R bimAb M26.1 used in this study
is secreted by a hybrid/hybridoma produced by somatic
fusion of the mAb MINT5 (mouse IgG1), which specifi-
cally recognizes the EGFR, and the hybridoma producing
mAb 298.1 (mouse IgG2a) that recognizes the human
T-cell receptor-associated CD3 complex. Generation of
the hybrid hybridoma and purification of bimAb have
been described in detail.19
Culture of Keratinocytes
Normal human exocervical keratinocytes were isolated
from hysterectomy specimens of women without disease
related to the cervix. Cell cultures were established and
maintained as described.20 This study protocol was ap-
proved by the Ethics Committee of the Faculty of Medi-
cine at the University of Lie`ge.
SiHa and CasKi are cervical carcinoma cell lines con-
taining, respectively, one copy21 and 600 copies of
integrated HPV16 DNA.22 C33 is a cervical carcinoma
cell line negative for HPV.23 KT1 and KT2 cell lines were
established by transfecting the full-length HPV16 ge-
nome, linearized at the BamHI site in pBR322-HPV16
plasmid, into short-term cultures of normal cervical kera-
tinocytes. This transfection was performed by electropo-
ration on 4.106 cells suspended in serum-free medium at
200 V and 950 F using a gene pulser system (BioRad,
Hercules, CA) as described previously.20 These cell lines
are tumorigenic in nude mice (unpublished observation).
All cell lines were maintained in Ham F12 (1:3) mixed with
Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc., Gaithersburg, MD), supplemented with 0.5 g/ml
hydrocortisone (Sigma, St. Louis, MO), 2 ng/ml EGF (Sig-
ma), 10% fetal calf serum, 2 nmol/L L-glutamine, 1 g/ml
fungizone, 1 mmol/L sodium pyruvate, and 3000 U/ml
penicillin-streptomycin (all from Life Technologies, Inc.).
For normal keratinocytes, we used the same medium
supplemented with 1010 mol/L cholera toxin, 5 g/ml
insulin, 20 g/ml adenine, 5 g/ml human transferrin, and
1.5 g/ml 3,3, 5-triiodo-L-thyronine (all from Sigma).
Isolation and Culture of T Lymphoblasts
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient (Ficoll-Hypaque) centrifugation
from heparinized blood of healthy donors or hysterecto-
mized patients, and cultured at 106 cells/ml with 50 IU/ml
rIL-2 (Biosource, Nirelles, Belgium) and phytohemagglu-
tinin (1 g/ml; Difco, MI) or anti-CD3 (OKT3, 10 ng/ml).
Culture medium was RPMI 1640 (Life Technologies, Inc.)
supplemented with 5% pooled AB serum and 2 mmol/L
L-glutamine (Life Technologies, Inc.). After 7 to 10 days of
subculture, 95% of cells consisted of CD3 T lympho-
blasts.
Lymphocytes used for organotypic cultures were la-
beled with the lipophilic fluorescent marker CM-DiL (Mo-
lecular Probes, Leiden, The Netherlands) according to
described procedures24 with minor modifications. Briefly,
lymphocytes were resuspended in 1 ml of phosphate-
buffered saline (PBS) and warmed to 37°C. The stock
solution of CM-DiL was diluted in 1 ml of PBS preheated
to 37°C for a final concentration of 16 g/ml. The dye was
mixed and immediately transferred to the cell suspen-
sion. Cells were incubated for 2 minutes at 37°C followed
by 2 minutes on ice, and washed in 40 ml of PBS at 4°C,
centrifuged, and resuspended in the appropriate me-
dium.
Cytotoxicity Assay
T lymphoblasts were used as effector cells in a 4-hour
51Cr-release assay at effector-target cell ratios ranging
from 50:1 to 5:1 with SiHa, CasKi, and C33, KT1, and
KT2, and normal keratinocytes as targets. Briefly, 5 103
51Cr-labeled target cells were added to various numbers
of effector cells in triplicate U-shaped 96-well microtiter
plates. For the evaluation of bimAb-triggering, M26.1
bimAb was added at various dilutions (1 to 1000 ng/ml) in
a final volume of 200 l. Parental 289.1 (anti-CD3) or
MINT-5 (anti-EGFR) mAb served as controls. After 4
hours of culture, 100 l of supernatant were removed and
evaluated for 51Cr-release in a -counter. Percent lysis
was calculated as described.25
Tumor Growth Inhibition Assay
Tumor growth inhibition was evaluated by a colorimetric
assay with MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphe-
nyl tetrazolium bromide) (Sigma) as described.26 Target
cells were seeded in triplicate at 7000/well for normal
keratinocytes, 5000/well for KT1 and KT2 cells, 3000/well
for C33 cells, and 2500/well for SiHa and CasKi cells, in
flat-bottomed 96-well plates, with different numbers of
effector cells and various mAb concentrations in 200 l of
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medium. After a 7-day incubation at 37°C, wells were
washed twice to remove nonadherent cells (effector cells or
dead target cells), and 100 l of fresh medium containing
0.5 mg/ml MTT was added to each well. Cells were incu-
bated for at least 4 hours at 37°C, and 100 l of 2-propanol
was added to each well, mixed thoroughly, and absor-
bance at 550 nm was determined in a microELISA reader
(BioRad microplate reader 550; BioRad, Hercules CA). Per-
cent growth inhibition was calculated as:
100 100 A sample A mediumA control A medium
where controls represent target cells grown in medium
alone. SD of triplicates never exceeded 5 to 10%.
Organotypic Cultures
Organotypic cultures of HPV-transformed and normal kera-
tinocytes were prepared as described.15 Briefly, dermal
equivalents were produced using collagen I (ICN, Asse-
Releigem, Belgium) containing 4  104 normal human fi-
broblasts. Then, 2.5  105 to 1  106 keratinocytes (HPV-
transformed or normal) were seeded on top of the gels and
kept submerged for24 hours. Rafts were then raised onto
a stainless metal grid and cells allowed to grow at the
air-liquid interface for 10 days. After stratification of keratin-
ocytes, T lymphoblasts, preincubated for 30 minutes with or
without 1 g/ml M26.1 bimAb or parental mAbs, were
seeded on top of the in vitro-formed epithelium at a concen-
tration of 5  105 or 2  106 cells/50 l of growth medium.
After 48 hours at 37°C, collagen rafts were harvested. Cul-
tures were embedded in OCT compound (Tissue Tek,
Sakura, The Netherlands) at 70°C and sectioned with a
cryostat microtome (Microm HM 5000 OM; Prosan, Merel-
beke, Belgium) for fluorescent microscopic analysis (Olym-
pus IX50, Micro Image 3.01.1 software).
Immunostaining
EGFR surface expression was evaluated on cells in
monolayers using the MINT-5 mAb (1 g/ml) followed by
a secondary FITC-conjugated goat anti-mouse IgG (Im-
munotech, France). Incubation of primary and secondary
antibodies was performed in PBS-bovine serum albumin
(0.03%) for 30 minutes on ice followed by washes.
Stained cells were analyzed on a FACScalibur sorter
(Becton Dickinson, Erembodegem, Belgium) using
CELLQuest software.
EGFR expression in biopsies of cervix and in organo-
typic cultures was assessed by immunohistochemistry
with the avidin-biotin-peroxidase technique (Vectastain
ABC Kit; Vector Laboratories, Burlingame, CA) using the
anti-EGFR mAb MINT5. Frozen sections (6 m) were
fixed in cold acetone for 3 minutes and endogenous
peroxidases were blocked with 0.1% H2O2 for 30 min-
utes. Sections were incubated sequentially with anti-
EGFR antibody (1 g/ml) or with isotype-matched control
antibody for 1 hour, with a biotinylated mouse anti-Ig
antibody for 30 minutes and with streptavidin/horserad-
ish/peroxidase/avidin/biotin complex for another 30 min-
utes. Positive cells were visualized using 3,3-diamino-
benzidine substrate (Prosan). Sections were
counterstained with methyl green.
Lymphocytes in organotypic cultures were immunohis-
tochemically stained using an anti-CD45 mAb (DAKO,
Belgium) followed by the same method as for EGFR
staining.
Measurement of Organotypic Culture Thickness
Thickness of the organotypic culture was evaluated by
the Micrometer program of the CAS “Cell Analysis Sys-
tems” (Becton Dickinson) and was expressed in m. The
complete section of the culture was screened and five
measurements were obtained for each field.
Terminal dUTP Nick-End Labeling (TUNEL)
Staining
Apoptotic cells were detected using the TUNEL tech-
nique (In Situ Cell Death Detection Kit; Roche, Germany).
Briefly, slides were fixed in cold acetone for 3 minutes,
washed twice with PBS, and 50 l of TUNEL reaction
mixture was added. After incubation in a humid chamber
for 1 hour at 37°C, slides were washed three times with
PBS, mounted, and examined by fluorescence micros-
copy (Olympus IX50, Micro Image software). Nuclei of all
cells were revealed with DAPI staining (4, 6-diamidine-
2-phenylindole dihydrochloride; Roche).
Enzyme-Linked Immunosorbent Assay (ELISA)
Levels of interferon- (IFN-) and tumor necrosis factor-
(TNF-) in the cultures were measured using specific
ELISA assays (Biosource, Nivelles, Belgium). Recombi-
nant human IFN- and TNF- were used as reference
standards.
Statistical Analysis
The nonparametric Mann-Whitney test was applied using
Instat Mac 2.01 software (GraphPad Software, San Diego,
CA). Differences were considered significant at P  0.05.
Results
Neoplastic HPV Keratinocytes Overexpress
EGFR
Fluorescence-activated cell sorting (FACS) analysis of
EGFR on cell surface revealed high expression levels of
EGFR on all HPV keratinocytes (HPV-transformed kera-
tinocytes KT1 and KT2 cells and tumor-derived SiHa and
CasKi cells) whereas HPV tumor cell line C33 showed
expression level as low as that of normal keratinocytes
(Figure 1A). EGFR was differentially expressed in the
epithelium of the uterine cervix and, interestingly, this
differential expression was also found in organotypic cul-
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tures as indicated by immunohistochemistry staining.
Indeed, staining was evident only in basal layers of
normal exocervix biopsies (Figure 1B) and of normal
keratinocyte organotypic cultures (Figure 1C), whereas
all cells were strongly stained in high-grade cervical
lesions (Figure 1D) and in organotypic cultures of
HPV cell lines CasKi, KT1 (Figure 1, E and F), KT2,
and SiHa (data not shown).
Allogeneic Lymphocytes Retargeted by BimAb
Kill HPV Keratinocytes in Monolayer Cultures
To evaluate the efficacy of bimAb against HPV keratin-
ocytes, cytotoxicity assay of lymphocytes retargeted by
the anti-CD3/anti-EGFR bimAb M26.1 was performed us-
ing normal and transfected cervical keratinocytes or cer-
Figure 1. EGFR expression on normal and HPV keratinocytes. A: EGFR expression by FACS analysis. Fluorescence index represents the total fluorescence
intensity in the presence of mAb MINT5 and FITC-labeled secondary antibodies/background level in the presence of the FITC-labeled secondary antibody alone.
Values are means (SD) of five independent experiments. B: Immunohistochemical staining with mAb MINT5 on biopsy specimens (original magnification,20)
of normal exocervix and high-grade squamous intraepithelial lesions (D), organotypic culture sections of normal keratinocytes (C), CasKi cells (E), and KT1 cells (F).
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vical carcinoma cell lines in monolayer cultures as targets
and lymphocytes from healthy donors as effectors. Cyto-
toxic assay revealed highly increased 51Cr release in
wells with activated T lymphocytes M26.1-retargeted and
EGFR target cells KT2, SiHa (Figure 2, A and B), and
CasKi (data not shown) as compared to activated lym-
phocytes incubated in absence of bimAb, which exerted
a low level of natural killer-like cytotoxic activity, particu-
larly evident at the higher E:T ratios. Parental antibodies
either alone or in combination failed to trigger cytolytic
activity against SiHa cells (Figure 2B) or against the other
targets (data not shown). A low but detectable cytolytic
activity was also observed against normal keratinocytes
(Figure 2C), which, as shown by FACS analysis, express
only low levels of EGFR. A similar lytic activity was ob-
tained against C33 HPV cells (data not shown), which
express EGFR at levels comparable to those of normal
keratinocytes.
In vivo, direct cytotoxicity is only one of the mecha-
nisms that lymphocytes could use to kill tumor cells.
Retargeted lymphocytes released cytokines able to in-
hibit the growth of tumor cells.26,27 Thus, we tested this
ability in a MTT tumor growth inhibition assay (Figure 2; D,
E, and F). The inhibitory effect of retargeted lymphocytes
on HPV-transformed keratinocytes KT2, CasKi (Figure 2,
D and E), and SiHa (data not shown) grown as monolay-
ers was much higher than that of lymphocytes alone,
whereas growth of normal keratinocytes was unaffected
at any E:T ratio tested (Figure 2F). Parental antibodies
have no effects at all (Figure 2; D, E, and F).
Allogeneic Lymphocytes Retargeted by BimAb
Kill HPV Keratinocytes in Organotypic Cultures
Infiltration of allogeneic-activated lymphocytes redi-
rected by bimAb M26.1 was evaluated in organotypic
cultures of HPV cell lines by staining the lymphocytes
with an anti-CD45 mAb (results in Figure 3, A to D, shown
for CasKi cells only). At both concentrations of lympho-
cytes tested (0.5 and 2  106 cells) infiltration by these
cells was observed (shown in Figure 3B for the higher
concentration). In the presence of activated lymphocytes
and bimAb M26.1 (1 g/ml), the thickness of CasKi or-
Figure 2. A–C: Cytotoxic activity of activated PBMCs in the presence or absence of anti-CD3/anti-EGFR bimAb M26.1 or of an equimolar mixture of the two
parental antibodies in a 4-hour 51Cr assay (only in B). D–F: Growth inhibition exerted by activated PBMCs in the presence or absence of anti-CD3/anti-EGFR
bimAb M26.1 or the mixture of the two parental antibodies (only in F) in a MTT assay. Experiments were done in triplicate. Lines with open symbols in graphs
A and D represent activity of autologous KT2 lymphocytes in the presence (triangles) or absence (squares) of M26.1. The other results were obtained with
allogeneic PBMCs. Data are the means of replicates in one representative experiment. Similar results were obtained in two to five independent experiments with
PBMCs from different healthy donors.
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ganotypic cultures was decreased (Figure 3C and Table
1) in correlation with the concentration of retargeted lym-
phocytes used (data not shown). In SiHa organotypic
cultures, culture thickness in the presence of retargeted
lymphocytes was also decreased as compared to SiHa
cells alone (Table 1), but to a lower extent than for CasKi.
Figure 3. A–D: Infiltration and effects of allogeneic activated PBMCs on organotypic cultures of Caski cells (original magnifications, 20). Lymphocytes were
detected by staining with an anti-CD45 mAb. Cultures were incubated with medium only (A), with 2  106 PBMCs alone (B), with 2  106 PBMCs retargeted
by bimAb M26.1 (C), or with 2  106 PBMCs incubated with anti-CD3 (298.1) and anti-EGFR (MINT5) mAbs at the same concentration as that of M26.1 bimAb
(D). Similar results were obtained in three independent experiments with allogeneic PBMCs from different healthy donors. E–G: Detection of apoptosis by TUNEL
assay in organotypic cultures of SiHa cells (original magnification, 20) incubated with medium alone (E), with 1 g/ml of bimAb M26.1 alone (F), or with 2 
106 allogeneic PBMCs retargeted by bimAb M26.1 (G). H: IFN- production in medium of SiHa organotypic cultures as detected by ELISA assay.
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Lymphocytes incubated with an equimolar mixture of
parental anti-CD3 (298.1) mAb and anti-EGFR (MINT5)
mAb showed no significant decrease in organotypic cul-
ture thickness (Figure 3D and Table 1).
The killing of HPV keratinocytes induced by bimAb-
retargeted lymphocytes was further examined by TUNEL
assay to detect apoptotic keratinocytes. In SiHa organo-
typic cultures without retargeted lymphocytes, only a few
apoptotic cells were present, probably because of spon-
taneous apoptosis (Figure 3E). In the presence of the
bimAb M26.1 alone (Figure 3F) or nonretargeted alloge-
neic PBMCs (data not shown), the number of apoptotic
cells was slightly increased. The addition of 2  106
lymphocytes and bimAb M26.1 significantly increased
the number of apoptotic cells (Figure 3G). Similar effects
were observed in CasKi organotypic cultures (data not
shown). Addition of parental mAb (MINT5 and 298.1) to
CasKi organotypic cultures led to a slight, but not signif-
icant, increase in apoptotic cell number (data not shown).
As already mentioned, retargeted lymphocytes might
also release cytokines. Thus, we analyzed the production
of IFN- and TNF- in organotypic cultures of SiHa cells
(Figure 3H) and CasKi cells (data not shown). IFN-
production was high in both cultures in the presence of
retargeted lymphocytes with 20- to 100-fold higher IFN-
level with 2  106 retargeted lymphocytes than in ab-
sence of bimAb. Parental antibodies used as controls
failed to induce IFN- production under the same exper-
imental conditions. For example, in CasKi organotypic
cultures, a production of 12 pg/ml with 2  106 PBMCs,
50 pg/ml with 2  106 PBMCs  parental mAb (MINT5/
298.1), and 321 pg/ml with 2 106 PBMCsM26.1 mAb
were observed. Production of TNF- in organotypic cul-
tures of SiHa and CasKi cells was increased at least
sevenfold in the presence of 2  106 retargeted alloge-
neic PBMCs relative to 2  106 PBMCs alone (data not
shown).
To evaluate the possible side effects of lymphocytes
retargeted by bimAb, organotypic cultures of normal
HPV keratinocytes were also analyzed. These cultures
incubated with lymphocytes retargeted by bimAb re-
vealed poor penetration of lymphocytes, with no signifi-
cant increase in the number of apoptotic cells. Both
apoptosis and lymphocyte infiltration were limited to the
superficial layers of the cultures (data not shown). A slight
decrease in the thickness of the epithelial sheet was
observed in these cultures in the presence of lympho-
cytes with or without bimAb (Table 1), probably because
of allogeneic response of lymphocytes.
Autologous Lymphocytes Retargeted by BimAb
Kill HPV Keratinocytes in Organotypic Cultures
The ability of lymphocytes retargeted by M26.1 bimAb to
lyse autologous HPV keratinocytes growing in mono-
layer or in organotypic culture was tested using periph-
eral blood lymphocytes of patients from which the HPV
cell lines KT1 and KT2 were derived. The M26.1-retar-
geted KT2 lymphocytes had cytotoxic effects and inhib-
ited the growth of the KT2 autologous cell line (Figure 2,
A and D) and of CasKi cells (data not shown) at levels
similar to those induced by healthy donors. In organo-
typic KT1cultures, the presence of autologous activated
lymphocytes and bimAb led to a significant decrease in
KT1 layer thickness (Figure 4 and Table 1) and this effect
was proportional to the number of lymphocytes present.
Consistent with the level of EGFR expression (see Figure
1A), the decreased thickness of the KT1 epithelial sheet
was intermediate between that of Caski and SiHa cells
(Table 1).
To identify the cell population (HPV keratinocytes,
lymphocytes, or both) undergoing apoptosis, lympho-
cytes were incubated with a red fluorescent lipophilic
tracer before seeding on organotypic cultures of KT1.
The majority of apoptotic cells were keratinocytes. Anal-
ysis of the number of apoptotic keratinocytes by TUNEL
staining in the presence of medium (Figure 4A), 2  106
autologous lymphocytes (Figure 4C), or 2  106 M26.1-
retargeted autologous lymphocytes (Figure 4E) revealed
the highest apoptotic index with the bispecific antibody.
These results were consistent with the thickness reduc-
tion (Figure 4, C and F, and Table 1). Superimposable
results were obtained with KT2 cells in three separate
experiments (Table 1). Moreover, IFN- (Figure 4B) and
TNF- (data not shown) production in the supernatant of
KT1 and KT2 (data not shown) organotypic cultures were
greatly increased in the presence of autologous lympho-
cytes retargeted by bimAb M26.1.
Discussion
The efficacy of immunotherapeutic protocols in preclini-
cal studies is generally evaluated in allogeneic human in
Table 1. Organotypic Culture Thickness
Target cells n Medium alone 2  106 PBMC 2  106 PBMC  M26.1 Thickness reduction, %‡
CasKi* 3 159  2 128  4§§ 78  3¶¶¶ 38–51
SiHa* 3 319  6 293  7 212  12¶ 28–37
Normal keratinocytes* 3 165  3 129  2§§§ 127  4 15–21
KT1† 1 137  2 119  3 63  2¶¶ 55
KT2† 3 171  3 140  2§ 97  1¶¶¶ 40–48
Data are given in m (mean  SE) from 1 to 3 independent experiments (n) with five separate measurements for each field.
*Target cells tested in the presence of allogeneic PBMCs.
†Target cells tested in the presence of autologous PBMCs.
‡Thickness reduction 2  106 bimAb-retargeted PBMCs versus medium alone.
§,¶P value  0.05; §§,¶¶P value  0.01; §§§,¶¶¶P value  0.001. Thickness of organotypic cultures treated with bimAb-retargeted PBMCs versus
PBMCs alone (¶), as well thickness of organotypic cultures with medium alone versus PBMCs alone (§) were compared. nd, not done.
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vitro models or in animals.26,28–31 Here, we demonstrated
the efficacy of lymphocytes redirected by a bimAb
against neoplastic keratinocytes in an autologous three-
dimensional culture model that closely mimics the in vivo
situation. BimAb-redirected lymphocytes were able to
reduce the thickness of autologous HPV organotypic
cultures and to induce keratinocyte apoptosis in these
cultures.
The bimAb M26.1 recognizes the CD3 and EGFR mol-
ecules, a 170-kd transmembrane glycoprotein with ty-
rosine kinase activity. EGFR is overexpressed in a wide
range of human malignancies4,32,33 and increased EGFR
expression is correlated with poor clinical outcome in
patients with cancer of the lung, bladder, esophagus,
breast, ovary, and cervix.4 In light of the contrasting
reports regarding EGFR up- and down-regulation3,34,35 in
cervical carcinogenesis,11 we also analyzed EGFR ex-
pression in cervical preneoplastic lesions and demon-
strated that EGFR expression in our model mimics the
situation observed in vivo. Indeed, EGFR was expressed
only in basal layers in normal exocervix, whereas all cells
in high-grade cervical lesions highly overexpressed
EGFR. These patterns were similar to those observed in
organotypic cultures with normal keratinocytes or HPV
lines. FACS analysis confirmed EGFR overexpression in
HPV cell lines compared with normal keratinocytes and
the HPV cell line C33 and several mechanisms have
been proposed to explain the EGFR overexpression by
HPV.9,10 The differential expression of EGFR on HPV
tumors might help to determine the bimAb concentrations
that cause preferential damage to malignant cells.
Reduced cancer cell growth when the EGFR transduc-
tion pathway is abrogated has been reported for diverse
therapeutic agents, including anti-EGFR monoclonal an-
tibodies.36 In our study, the parental anti-EGFR mAb
(MINT-5) weakly inhibited the growth of HPV keratino-
cytes in monolayer cultures. Similarly, in organotypic cul-
tures of HPV cell lines incubated with MINT-5 alone or
with M26.1 bimAb alone, the number of apoptotic kera-
tinocytes slightly increased but culture thickness was not
reduced. This slightly increased apoptosis with M26.1
alone could be related to the blockage of EGFR, and
indirectly to the inhibition of autocrine EGF or transform-
ing growth factor- activity. Accordingly Tosi and collab-
orators6 have demonstrated that the F(ab)2 fragment of
MINT-5 (the anti-EGFR component of M26.1) inhibits
Figure 4. Detection of autologous lymphocyte infiltration and apoptosis in organotypic cultures of KT1 cells (original magnification, 20). C and E: Staining of
apoptotic cells by TUNEL assay (green cells) and infiltrating lymphocytes (red cells). D and F: The corresponding nuclei stained with DAPI. Organotypic
KT1cultures were incubated with medium alone (A, TUNEL and DAPI staining are merged in this panel and very few apoptotic cells are present), 2  106
autologous PBMCs alone (C and D), or 2  106 autologous PBMCs retargeted by M26.1 bimAb (E and F). B: IFN- production in medium of KT1 organotypic
cultures as detected by ELISA assay.
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EGFR tumor growth both in vitro and in vivo by interfering
with transforming growth factor-/EGF autocrine loops.
Thus, the action of anti-EGFR mAb alone might be de-
layed compared with that of bimAb retargeted-lympho-
cytes and might appear after more than 48 hours of
incubation. A major advantage of the bimAb-retargeting
approach compared to the use of an anti-EGFR antibody
alone is the induction of cytolysis and apoptosis of kera-
tinocytes, resulting from the attack by bimAb-armed lym-
phocytes in addition to the blocking of the EGF pathway.
Such tumor cell death provides a new source of antigens
for the immune system, which might be relevant in light of
recent evidence indicating that not only necrotic but also
apoptotic cells can be captured by antigen-presenting
cells and act as an antigen source for a specific T-cell
response.37,38
Finally, bimAb-targeted T cells might also induce a
local release of cytokines at the tumor site.27 Despite the
fact that cytokines production may differ donor to donor,
we observed an increased production of IFN- and
TNF- in organotypic cultures of HPV cell lines in the
presence of retargeted lymphocytes. The cytokine levels
were generally higher with allogeneic PBMCs. This differ-
ence could be because of an allo-MHC recognition that
may synergize with bimAb effect and further enhance
IFN- and TNF- release. These two cytokines have
pleiotropic biological activities, including anti-prolifera-
tive, anti-viral, and immunomodulatory effects.39,40 Direct
effects of these cytokines on the growth HPV-transformed
keratinocytes in monolayer and in organotypic cultures
have been reported.13 Tumor growth inhibition induced
by IFN- and TNF- has been also demonstrated for
other tumors.41–43 Moreover, IFN- and TNF- could ini-
tiate a local inflammatory response and indirectly attract
antigen-presenting cells, which may be rare in cancers.44
In particular, the presence of IFN- in the microenviron-
ment could induce the T-helper 1 polarization of the T cell
response that is associated with anti-tumor protection.45
Furthermore, IFN- has been shown to enhance MHC
class I molecule expression, which is frequently down-
regulated in tumor cells.46,47 IFN- is also known to up-
regulate the expression of ICAM-1 on HPV-transformed
keratinocytes,48 which is important for the infiltration of
lymphocytes into squamous lesions because stimulated
lymphocytes express high levels of the ICAM-1 ligand
LFA-1.49 Up-regulation of ICAM-1 expression increases
the susceptibility of tumor cells to bimAb-targeted lysis
because the LFA-1/ICAM-1 cell adhesion pathway is in-
volved in this mechanism.50
Human squamous epithelia express low to moderate
levels of EGFR35 raising the possibility of significant side-
effects associated with the systemic use of anti-CD3/anti-
EGFR antibody in humans. However, the F(ab)2 of this
bispecific antibody can be used for local treatment at the
site of the primitive tumor or for example, in serosal
cavities. Some results have been already published
about the in vivo anti-tumor efficacy of bimAb M26.1, eg,
mean survival time of nude mice bearing human ovarian
tumor xenografts was significantly increased after treat-
ment with M26.1 bimAb-coated lymphocytes.28 The po-
tential immunogenicity of murine antibodies poses an-
other problem in humans. However, advances in
molecular genetics and protein engineering have led to
new formats for recombinant bispecific antibodies, such
as single-chain bispecifics, bispecific diabodies, and
bispecific minibodies made from humanized or even fully
human antibodies.51
In conclusion, our data demonstrate that a lymphocyte/
M26.1 bimAb approach is efficient in killing autologous
neoplastic keratinocytes in an in vitro model exhibiting many
features of a squamous cell cancer on a mucosal surface.
Together, the findings suggest the usefulness of bimAb in
immunotherapeutic protocols for epithelial cancers.
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